This week we review disturbing vaccine study requirements, CBD an incredible gem if possibly protecting the lungs and restoring oxygen levels, and a strong correlation as to shoes being an unrecognized major disease vector. In addition to looking at COVID data correlations to which countries are locking down in response Sars-COV-2 to those which have not or have done little. #covidvaccine #covidvector #covidnews Data Sources API for DataFrames: The COVID Tracking Project Our wold in Data (Oxford) Links: https://www.eurekalert.org/pub_releases/2020-10/uoo-ecw102220.php#.X5N_7_DuPM0.wordpress https://www.eurekalert.org/pub_releases/2020-10/b-cvt102020.php#.X5OGbCHAYR8.wordpress https://www.eurekalert.org/pub_releases/2020-10/mcog-chr101620.php#.X45lOsCeu4k.wordpress https://wwwnc.cdc.gov/eid/article/26/7/20-0885_article
Our weekly review of the current COVID data and country comparisons as well as other oddities such as Mask Litter, Trash Cans, and Shoes being unintended spreaders. All this under the guise of Amateur Python Analytics. Brief CSV File Request Code below (Pandas). That will allow you to pull Oxford University Data up to the current date. Enjoy 😉
This is a long one, next week I will make it A LOT shorter.
#covid19 #sarscov2 #data
import pandas as pd
younameit = pd.read_csv(‘https://covid.ourworldindata.org/data/owid-covid-data.csv’)
Armstrong Institute researchers discover missed medical conditions in more than 1 in 4 critically ill adults
Each year as many as 40,500 critically ill U.S. hospital patients die with an unknown medical condition that may have caused or contributed to their death, Johns Hopkins patient safety experts report in a recent study.
In a discussion of their findings, described online in BMJ Quality & Safety, researchers say that although diagnostic errors in the intensive care unit (ICU) may claim as many lives each year as breast cancer, they remain an underappreciated cause of preventable patient harm.
“Our study shows that misdiagnosis is alarmingly common in the acute care setting,” says Bradford Winters, M.D., Ph.D., lead author and associate professor of anesthesiology and critical care medicine and neurology and surgery in the Johns Hopkins University School of Medicine. “To date, there’s been very little research to determine root causes or effective interventions,” Winters says, noting that less lethal patient safety risks have received greater attention.
By reviewing studies that used autopsy to detect diagnostic errors in adult ICU patients, the experts in the Johns Hopkins Armstrong Institute for Patient Safety and Quality discovered that 28 percent of patients — more than one in four — had at least one missed diagnosis at death. In 8 percent of patients, the diagnostic error was serious enough that it may either have caused or directly contributed to the individual’s death and, if known, likely would have changed treatment, researchers say. Infections and vascular maladies, such as heart attack and stroke, accounted for more than three-quarters of those fatal flaws.
Overall, the medical conditions most commonly missed by diagnosticians included heart attack; pulmonary embolism, an artery blockage in the lungs; pneumonia; and aspergillosis, a fungal infection that most commonly affects individuals with a weakened immune system. Cumulatively, these four conditions accounted for about one-third of all illnesses that doctors failed to detect.
Their review of 31 studies included 5,863 autopsies from a wide range of ICU types. The prevalence of autopsy-detected misdiagnoses, which were stratified by severity, ranged from 5.5 to 100 percent by study. Winters and his team categorized misdiagnoses based on four categories: vascular, which included conditions involving vessel blockages and bleeding, such as heart attack and stroke; all bacterial, viral and fungal infections; mechanical pathophysiological, a broad range of organ malfunction such as congestive heart failure and bowel obstruction; and cancer/other.
After collecting and classifying all error data, the researchers calculated how frequently misdiagnoses would be discovered if every patient who died in the ICU underwent an autopsy. Although autopsy is more frequently performed in complex patient cases in which the clinician may have a lower level of diagnostic certainty, the authors took this potential bias into account. Based on those adjustments, they say their calculations are conservative estimates.
Winters and his colleagues also found that, when compared with adult hospital patients overall, individuals in the ICU face up to a twofold risk of suffering a potentially fatal diagnostic mistake.
“It may be counterintuitive to think that the patients who are the most closely monitored and frequently tested are more commonly misdiagnosed, but the ICU is a very complex environment,” Winters says. Clinicians face a deluge of information in a distracting environment in which the sickest patients compete for attention, most without being able to communicate with their medical team. “We need to develop better cognitive tools that can take into account the 7,000 or more pieces of information that critical care physicians are bombarded with each day to ensure we’re not ruling out potential diagnoses,” Winters says.
Although two-thirds of discovered misdiagnoses did not directly contribute to the patient’s death, Winters says they’re an important indicator of accuracy and aren’t without costs. Patients may endure lengthened hospital stays, unnecessary surgical procedures and reduced quality of life because of non-fatal diagnostic mistakes, Winters adds.
The Armstrong Institute patient safety experts say the study points to the need for additional research to pinpoint the causes of misdiagnosis and identify tools to help diagnosticians more accurately assess patients.
This research was supported by a National Institute of Health training grant awarded to the Johns Hopkins University School of Medicine and a grant from the Agency for Healthcare Research and Quality (HS017755-01).
Other Johns Hopkins researchers who contributed to this study include Jason Custer, M.D.; Samuel M. Galvagno Jr., D.O., Ph.D.; Elizabeth Colantuoni, M.S., Ph.D.; Shruti G. Kapoor, M.D.; HeeWon Lee, B.A.; Victoria Goode, M.B.A., M.L.I.S.; Karen Robinson, M. Sc., Ph.D.; Atul Nakhasi, B.A.; and Peter Pronovost, M.D., Ph.D.
For more information:
Johns Hopkins study of ingredient in ‘magic mushrooms’ found participants exhibited more ‘openness’
A single high dose of the hallucinogen psilocybin, the active ingredient in so-called “magic mushrooms,” was enough to bring about a measureable personality change lasting at least a year in nearly 60 percent of the 51 participants in a new study, according to the Johns Hopkins researchers who conducted it.
Lasting change was found in the part of the personality known as openness, which includes traits related to imagination, aesthetics, feelings, abstract ideas and general broad-mindedness. Changes in these traits, measured on a widely used and scientifically validated personality inventory, were larger in magnitude than changes typically observed in healthy adults over decades of life experiences, the scientists say. Researchers in the field say that after the age of 30, personality doesn’t usually change significantly.
“Normally, if anything, openness tends to decrease as people get older,” says study leader Roland R. Griffiths, a professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine.
The research, approved by Johns Hopkins’ Institutional Review Board, was funded in part by the National Institute on Drug Abuse and published in the Journal of Psychopharmacology.
The study participants completed two to five eight-hour drug sessions, with consecutive sessions separated by at least three weeks. Participants were informed they would receive a “moderate or high dose” of psilocybin during one of their drug sessions, but neither they nor the session monitors knew when.
During each session, participants were encouraged to lie down on a couch, use an eye mask to block external visual distraction, wear headphones through which music was played and focus their attention on their inner experiences.
Personality was assessed at screening, one to two months after each drug session and approximately 14 months after the last drug session. Griffiths says he believes the personality changes found in this study are likely permanent since they were sustained for over a year by many.
Nearly all of the participants in the new study considered themselves spiritually active (participating regularly in religious services, prayer or meditation). More than half had postgraduate degrees. The sessions with the otherwise illegal hallucinogen were closely monitored and volunteers were considered to be psychologically healthy
“We don’t know whether the findings can be generalized to the larger population,” Griffiths says.
As a word of caution, Griffiths also notes that some of the study participants reported strong fear or anxiety for a portion of their daylong psilocybin sessions, although none reported any lingering harmful effects. He cautions, however, that if hallucinogens are used in less well supervised settings, the possible fear or anxiety responses could lead to harmful behaviors.
Griffiths says lasting personality change is rarely looked at as a function of a single discrete experience in the laboratory. In the study, the change occurred specifically in those volunteers who had undergone a “mystical experience,” as validated on a questionnaire developed by early hallucinogen researchers and refined by Griffiths for use at Hopkins. He defines “mystical experience” as among other things, “a sense of interconnectedness with all people and things accompanied by a sense of sacredness and reverence.”
Personality was measured on a widely used and scientifically validated personality inventory, which covers openness and the other four broad domains that psychologists consider the makeup of personality: neuroticism, extroversion, agreeableness and conscientiousness. Only openness changed during the course of the study.
Griffiths says he believes psilocybin may have therapeutic uses. He is currently studying whether the hallucinogen has a use in helping cancer patients handle the depression and anxiety that comes along with a diagnosis, and whether it can help longtime cigarette smokers overcome their addiction.
“There may be applications for this we can’t even imagine at this point,” he says. “It certainly deserves to be systematically studied.”
Along with the National Institute on Drug Abuse, this study was funded by the Council on Spiritual Practices, Heffter Research Institute and the Betsy Gordon Foundation.
Other Hopkins authors of the research include Matthew W. Johnson, Ph.D, and Katherine A. MacLean, Ph.D.
Johns Hopkins Medicine Media Relations and Public Affairs Media Contact: Stephanie Desmon 410-955-8665 firstname.lastname@example.org